Vero cell

Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Retrieved on: 
Wednesday, November 9, 2022
Health, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Respiratory syncytial virus, Plasma, Marketing, Omicron, Ritonavir, Adult, Hepatitis B virus, Patent, U.S. Securities and Exchange Commission, Severe acute respiratory syndrome coronavirus 2, HBV, Food, Glecaprevir/pibrentasvir, Degenerative disease, Risk, Research, RSV, Tissue, Human, SPRINT, Alpha, Drug discovery, HCV, Regulation of tobacco by the U.S. Food and Drug Administration, NASDAQ, Fast Track, Patient, Safety, Infection, Pharmacokinetics, Disease, Security (finance), Industry, AbbVie, Vero cell, Medication, COVID-19, Pharmaceutical industry

The study is designed to evaluate the safety, tolerability, and antiviral activity of 200mg and 400mg once-daily doses of EDP-235 compared to placebo.

Key Points: 
  • The study is designed to evaluate the safety, tolerability, and antiviral activity of 200mg and 400mg once-daily doses of EDP-235 compared to placebo.
  • The initiation of SPRINT is an important milestone in advancing the clinical development of EDP-235 as a once-daily antiviral treatment for COVID-19.
  • Patients will receive EDP-235 orally at a dose of 200mg or 400mg or placebo once daily for five days.
  • EDP-235, Enantas lead 3CL protease inhibitor (also known as main protease or Mpro), which has Fast Track designation from the U.S. Food and Drug Administration, was specifically designed for the treatment of COVID-19.

Sense and Biotecom Agree to Distribute Rapid, Instrument-Free Molecular Test, Veros COVID-19 in Chile

Retrieved on: 
Wednesday, November 2, 2022
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Veros, CEO, Health, Hospital, Sense, Omicron, COVID-19, WHO, Laboratory, Molecular biology, Diagnosis, Vero cell, Product life-cycle theory, Interest, Company, Point-of-care testing, US, Patient, CDC, Biotechnology, Solution, Trial of the century, Pharmaceutical industry, Delta

Global molecular diagnostics innovator Sense Biodetection (Sense) today announced it has entered into a strategic agreement with Biotecom for the non-exclusive distribution in Chile of Senses Veros instrument-free, point-of-care molecular testing platform.

Key Points: 
  • Global molecular diagnostics innovator Sense Biodetection (Sense) today announced it has entered into a strategic agreement with Biotecom for the non-exclusive distribution in Chile of Senses Veros instrument-free, point-of-care molecular testing platform.
  • This agreement is significant for Sense as it marks our entry into the South American market, said Sense Chief Commercial Officer Ryan Roberts.
  • Founded in 2013, Biotecom is a leading specialty medical distributor of biotechnology and molecular devices serving Chilean hospitals, laboratories, and clinics.
  • In the continuously growing molecular biology segment, Biotecom will always focus on bringing customers the best solutions available.

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

Retrieved on: 
Friday, July 29, 2022
Health, FDA, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Severe acute respiratory syndrome coronavirus 2, Medication, Half-life, Vero cell, Degenerative disease, Industry, Tissue, HCV, U.S. Securities and Exchange Commission, RSV, Research, Headache, Fast Track, Drug discovery, Hepatitis B virus, Respiratory syncytial virus, Marketing, Ritonavir, Human, Patent, Adult, Safety, COVID-19, NASDAQ, Institute of Liver and Biliary Sciences, Alpha, PK, AbbVie, FDA, Security (finance), AES, Nausea, COVID, Pharmacokinetics, Glecaprevir/pibrentasvir, Risk, Plasma, HBV, Pharmaceutical industry, Perfume, SAD, Delta, Vero

EDP-235, a coronavirus 3CL protease inhibitor, which received Fast Track designation from the U.S. Food and Drug Administration (FDA), is specifically designed to be a once-daily, oral antiviral treatment for COVID-19.

Key Points: 
  • EDP-235, a coronavirus 3CL protease inhibitor, which received Fast Track designation from the U.S. Food and Drug Administration (FDA), is specifically designed to be a once-daily, oral antiviral treatment for COVID-19.
  • Our data support a convenient dosing regimen, with strong exposure multiples for both the 200mg and 400mg doses, without the need for ritonavir boosting.
  • To optimize dose selections, the study evaluated a broad range of single and multiples doses in fasted and fed states.
  • EDP-235, Enantas lead 3CL protease inhibitor, which has Fast Track designation, is being developed for the treatment of COVID-19.

Sense and Cruinn Diagnostics Sign Distribution Agreement to Market Veros COVID-19 in Ireland

Retrieved on: 
Thursday, March 17, 2022
Health, Medical Devices, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Veros, Omicron, Point-of-care testing, University, US, Patient, Health, Partnership, WHO, Mark (given name), Laboratory, FDA, Veterinary medicine, COVID-19, Clinical, Use, CE marking, Marketing, View, Pharmaceutical industry, Medical device, Vero cell, EU, Oireachtas Rince na Cruinne, Delta

Global molecular diagnostics innovator, Sense Biodetection (Sense), announced today that it had entered into a strategic distribution agreement with Cruinn Diagnostics Ltd. (Cruinn) for the Irish market.

Key Points: 
  • Global molecular diagnostics innovator, Sense Biodetection (Sense), announced today that it had entered into a strategic distribution agreement with Cruinn Diagnostics Ltd. (Cruinn) for the Irish market.
  • Cruinn, a leading supplier in the healthcare and laboratory market, is among the network of planned EU distribution partners authorized to market Veros COVID-19.
  • Cruinns reputation for customer service and innovative point-of-care products is best in class in its market, commented Ryan Roberts, Chief Commercial Officer of Sense.
  • This will be the first instrument-free molecular test for COVID-19 to enter the Irish market, highlighting the strategic importance of this agreement to Cruinn, said Aidan Wearen, head of Marketing and Sales for Cruinn.

Sense Receives CE Marking for Veros™ COVID-19 Rapid, Instrument-Free Molecular Test

Retrieved on: 
Tuesday, March 8, 2022
Health, Medical Devices, Infectious Diseases, Other Health, Other Science, Science, Biotechnology, Veros, CE marking, WHO, Patient, Interest, Point-of-care testing, VP, RSV, FDA, US CDC, Sense, Use, US, COVID-19, Pharmacy, Concern, CE, Health, Vero cell, Mark (given name), PCR, Infection, Pharmaceutical industry, Medical device, Omicron, Delta

Global molecular diagnostics innovator, Sense Biodetection (Sense), today announced receipt of CE Marking for Veros COVID-19, the first and only fully integrated, easy-to-use molecular diagnostic test that provides laboratory-quality results in 15 minutes.

Key Points: 
  • Global molecular diagnostics innovator, Sense Biodetection (Sense), today announced receipt of CE Marking for Veros COVID-19, the first and only fully integrated, easy-to-use molecular diagnostic test that provides laboratory-quality results in 15 minutes.
  • Sense anticipates launching Veros COVID-19 in Europe this quarter, initially in Ireland, Benelux and the Nordic regions.
  • Analytical performance testing has demonstrated that Veros COVID-19 is over 1,000 times more sensitive than widely used antigen tests.
  • Veros COVID-19 results were compared directly against a highly-sensitive, CE Marked and WHO & US FDA emergency authorized qRT-PCR test, from a world-leading developer and manufacturer of laboratory diagnostics.

Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

Retrieved on: 
Wednesday, May 20, 2020
Viruses, Nidovirales, Animal virology, Zoonoses, Coronaviridae, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, In vitro, Vero cell, CoV, Middle East respiratory syndrome-related coronavirus

The preliminary study results show that AT-H201 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which are the standard cell types being used to study infectivity of the coronavirus.

Key Points: 
  • The preliminary study results show that AT-H201 inhibits SARS-CoV-2 infectivity of VERO cells in a laboratory culture, which are the standard cell types being used to study infectivity of the coronavirus.
  • Significant findings from the testing include:
    AT-H201 components inhibited SARS-CoV-2 from infecting VERO cells in a laboratory culture.
  • Potency was measured by microscopic examination of the cytopathic effect caused by SARS-CoV-2 in VERO cells.
  • Successful in vitro tests do not guarantee similar results from in vivo studies, including in human clinical trials.